Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis.

摘要: Abstract Combined chemotherapy has demonstrated a degree of efficacy in gastric carcinoma. As 5-fluorouracil (5FU) and cisplatinum are two the most active drugs, we have tested combined 5FU prospective phase II trial. Cycles were administered every 4 weeks consisted 1000 mg/m 2 /day 5 days continuous intravenous (i.v.) infusion 100 on day 2. repeated according to tolerance efficacy. 87 patients entered study, 57 with metastatic or recurrent tumour (M) 30 locally advanced cancer (LAGC). The response rate for 83 evaluable was 43% [95% confidence interval (CI) 30–56%]. There four complete responses (5%), 32 partial (39%), 34 cases stable disease 13 progressive disease. Responses more frequent good performance status ( P = 0.02), their primary located cardia 0.003), non-linitis plastica form 0.003) containing less than 50% independent cells 0.016). Median survival 9 months total population. It better 0.01), those who did not linitis 0.005). Toxicity acceptable, although grade 3–4 neutropenia reported 22% cycles, mucositis 14% 3 died septic complications. combination is effective terms warrants testing other regimens.